Radiopharmaceuticals

For patients

 

Suspicion or detection of cancer is a tremendous psychological shock for both the patient and his family. It is widely believed that cancer is always lethal. However, the true is that early detection of cancer often leads to complete cure, and that cancer diagnosed even in advanced stage let for long life when proper treatment is introduced and monitored. Contemporary medicine has a highly effective diagnostic tool, such as PET-CT, giving patients an invaluable chance in the fight against cancer.

shutterstock 3175735311

 

PET/CT

For contemporary medicine as important as the treatment itself is modern, non-invasive and precise diagnostics. Its development in recent years, thanks to state-of-the-art technologies, gives physicians possibilities  which were not available until now.

The most valuable information is provided by imaging studies. One of the newest and still rapidly developing diagnostic methods is PET/CT - Positron Tomography combined with X-ray Computed Tomography. This technique allows you to thoroughly examine the whole body in a matter of minutes and obtain the most accurate results that you can get at the current state of knowledge.

The combination of radioisotope methods, showing life processes and X-ray images showing anatomical images, enables cell-tissue pathology detection, which is particularly important for identifying early cancer lesions. PET/CT helps to diagnose a disease, select a treatment, monitor its progress, prevent relapse being widely used in oncology, cardiology and neurology.

 

shutterstock 743085161

 

HOW DOES IT WORK

To obtain such a precise image showing the vital functions of individual tissues and organs, the patient receives intravenously a suitable tracer - a naturally absorbed compound (e.g. glucose), labelled by short-lived radioisotope, named radiopharmaceutical. This compound is distributed all over the body with blood stream but is also very quickly decayed, making the test harmless and radiation dose safe for the patient.

Radiopharmaceutical accumulates in the cells and is detected by the super sensitive PET/CT scanner, giving an image of extraordinary precision. Usually diseased cells accumulate tracer differently than the healthy ones, it is possible to visualize and locate abnormalities at the cell or cell group level, even if the anatomically defined tissue fragment is no different from the surrounding tissue. This allows for a very accurate identification and localization of even small tumor lesions.

The key to getting such images is precise radiopharmaceuticals. Currently, around 200 different radioactive labelled compounds are used worldwide, depending on which organ or part of the body is examined.

 

HAJ 5037m

 

HOW RADIOPHARMACEUTICAL ARE MANUFACTURED ?

It's a rather complicated process that requires advanced technology and precision, with restrictive quality requirements, radiopharmaceuticals are produced only by highly specialized companies.. Production consists of two steps. In the first step short-lived radioactive isotope must be produced, the second is the synthesis of the appropriate compound labelled with the radioisotope to obtain the required radiopharmaceutical. Then the manufactured material passes through detailed quality control, using very sensitive, certified equipment. Highly qualified staff, laboratories equipped with state-of-the-art laboratory equipment and best international manufacturing standards, are required to obtain safe, stable, sterile, reliable and repeatable radiopharmaceuticals.

 

HAJ 5117 2m2

 

Radiopharmaceuticals, by their nature, have a very short shelf-life, their production, shipment and administration take place in a short and precise time, this is why are transported from the production site to the PET/CT or PET/MR sites with special privileged vehicles moving like ambulances or airplanes.

 

shutterstock 46244022

 

 

WE WORK FOR THE FUTURE

SYNEKTIK PHARMA produces radiopharmaceuticals in Poland and distributes them in Poland and abroad.

Research and Development Center established by Synektik, in cooperation with Polish and foreign scientific centers, works on new PET tracers, because they are the future of diagnostic based on PET technology.

 

 


Product


Description

Patient Information Leaflet



 IASON Efdege® 


Tracer for use with positron emission tomography (PET) in oncological, cardiological, neurological, and infectious and inflammatory diseases diagnostic procedures

Patient Information Leaflet
EFDEGE®
1 GBq/ml




IASOflu®



Tracer for use with positron emission tomography (PET) in diseases where abnormally altered osteogenic activity is the diagnostic target


Patient Information Leaflet
IASOflu® 2 GBq/ml



IASOcholina®


Tracer for use with positron emission tomography (PET) in detection of bone metastases of prostate cancer and hepatocellular carcinoma

Patient Information Leaflet
IASOcholine®
1 GBq/ml



IASOdopa®


Tracer for use with positron emission tomography (PET) in oncological and neurological diagnostic procedures

Patient Information Leaflet
IASOdopa®
0.3 GBq/ml




IASOglio®


Tracer for use with positron emission tomography (PET) when enhanced amino acids  consumption of sick organs or tissues is the diagnostic target


Patient Information Leaflet
IASOglio®
2 GBq/ml


GalliaPharm®
Ge-68/Ga-68 generator


Pharmaceutical product for obtaining the positron emitter Gallium (68) for production of labelled tracers (for example peptides)

Patient Information Leaflet
GalliaPharm®, 0.74-1.85 GBq, radionuclide generator
 

 

Glunektik®

 

Tracer for use with positron emission tomography (PET) in oncological, cardiological and neurological diagnostic procedures and infectious and inflammatory diseases

 

Patient Information Leaflet
Glunektik®
1 GBq/ml

 

Fluorocholine (18F) Synektik®


Tracer for use with positron emission tomography (PET) in detection of bone metastases of prostate cancer and hepatocellular carcinoma

Patient Information Leaflet
Fluorocholine (18F) Synektik® 
1 GBq/ml

 

Fludeoxyglucose (18F) Synektik®

Tracer for use with positron emission tomography (PET) in oncological, cardiological, neurological, and infectious and inflammatory diseases diagnostic procedures
Patient Information Leaflet Fludeoxyglucose (18F) Synektik® 200-2200 MBq/ml 

 

MonFCH®

Tracer for use with positron emission tomography (PET) in detection of bone metastases of prostate cancer and hepatocellular carcinoma
Patient Information Leaflet
MonFCH® 910-3415 MBq/ml